Business
Interim Results for six months ended 30 June 2022
Interim Results for six months ended 30 June 2022.
About this update from Arecor Therapeutics Plc
[{"type":"text","content":"\n \n \n \n Arecor Therapeutics plc\n \n \n \n \n (\"Arecor\", the \"Company\" or the \"Group\")\n \n \n \n \n \n \n \n \n \n INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2022\n \n \n \n \n \n \n \n \n - Excellent progress across proprietary clinical pipeline with key data for ultra-rapid acting insulin AT247 expected in H2\n \n \n \n \n \n \n \n - Continued strong progress across partnered programmes with addition of a new collaboration with a Top 5 global pharmaceutical company\n \n \n \n \n \n \n \n - Acceleration of commercially driven strategy, with post-period acquisition of Tetris Pharma Ltd (\"Tetris Pharma\") and £6 million Placing to add key commercial diabetes product and build out Arecor's specialty hospital products franchise with scalable sales, marketing and distribution platform\n \n \n \n \n \n Cambridge, UK, 8 September 2022: Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical company advancing today's therapies to enable healthier lives, today announces its interim results for the six months ended 30 June 2022.\n \n \n \n \n \n \n Sarah Howell, Chief Executive Officer of Arecor, said\n \n : \"Arecor's ambition is to build a significant self-sustaining biopharmaceutical company and we expect the next six months to bring further progress within our diabetes franchise and continuing discussions with potential partners to expand our portfolio of revenue generating partnership deals. Clinical data for AT247 is expected later in 2022 and is key to further demonstrating its superiority against current gold standard treatments and its potential to\n \n facilitate a fully closed loop artificial pancreas. This could provide a significant inflexion point for the Group. In H2, we also expect to initiate a further clinical trial for AT278 in people living with Type 2 diabetes\".\n \n \n \n \n \n \n \n \n \n \"Our acquisition of Tetris Pharma brings an opportunity to accelerate our commercially-driven strategy alongside our core diabetes and partnered programmes. We have gained a revenue-generating sales, marketing and distribution platform which complements our existing specialty hospitals products franchise. The lead product, Ogluo®, meets a key patient need for people living with diabetes at risk of severe hypoglycaemia, which is a ther...